Table 3.

Hazard Ratios (95% CI) for all CVD, CHD and HF excluding women taking hormone therapy (n = 1,934)^*,†,‡

	CVD	CHD	HF
	212/1,934, IR = 10.3	127/1,934, IR = 6.1	81/1,934, IR = 3.9
Total T (nmol/L)	1.13 (0.99, 1.31)	1.19 (0.99, 1.43)	1.17 (0.93, 1.48)
Bioavailable T (nmol/L)	1.09 (0.93, 1.29)	1.07 (0.87, 1.31)	1.19 (0.91, 1.56)
Free T (Percent)	0.86 (0.69, 1.08)	0.71 (0.54, 0.93)	0.77 (0.54, 1.09)
Estradiol (nmol/L)	0.97 (0.78, 1.19)	0.76 (0.58, 0.99)	0.75 (0.54, 1.04)
Total T/estradiol ratio	1.21 (0.99, 1.48)	1.55 (1.20, 2.00)	1.51 (1.10, 2.06)
DHEA (nmol/L)	0.98 (0.84, 1.13)	1.01 (0.83, 1.22)	0.88 (0.69, 1.12)
SHBG (nmol/L)	1.14 (0.93, 1.41)	1.39 (1.07, 1.82)	1.25 (0.89, 1.75)

^*Abbreviations: CVD, cardiovascular disease; CHD, coronary heart disease; HF, heart failure; IR, incidence rates; T, testosterone; DHEA, dehydroepiandrosterone; SHBG, sex hormone binding globulin; HDL, high density lipoprotein; eGFR; estimated glomerular filtration rate; CRP, C-reactive protein; IL-6, interleukin-6.

^†All sex-hormones are log-transformed and standardized. Hazard Ratios are associated with 1 SD increase in log sex hormones.

^‡Model adjusts for age (year, continuous), race/ethnicity (white, black, Hispanic, and Chinese), and study site (CA, MN, NY, IL, NC, and MD), education (<high school, high school, >high school), waist to hip ratio (continuous), physical activity, and smoking (never, former, current), systolic blood pressures (mmHg, continuous), use of antihypertensive medications (yes, no), total cholesterol (mg/dl, continuous), HDL-cholesterol (mg/dl, continuous), use of lipid lowering medications (yes, no), diabetes (yes, no), eGFR (mL/min/1.73 m2), CRP (mg/l, log-transformed continuous), IL-6 (pg/ml, log-transformed, continuous), fibrinogen (mg/dl, log-transformed continuous), D-dimer (ug/ml, log-transformed continuous).